Form 4: Sarepta Therapeutics Director Hans Wigzell Exercises Options and Sells Shares
SEC Form 4 Filing
Director Hans Wigzell exercised stock options and sold shares of Sarepta Therapeutics on March 8, 2024.
Summary
- On March 8, 2024, Hans Wigzell, a director of Sarepta Therapeutics, exercised stock options to acquire 15,000 shares of common stock at a price of $13.90 per share.
- Following the exercise of options, Wigzell sold a total of 15,000 shares in multiple transactions at weighted average prices of $123.85, $123.10 and $122.39.
- After these transactions, Wigzell directly owns 22,840 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, although it is a common practice.
Key Dates
| Date | Description |
|---|---|
| 02/27/2016 | Original date of stock option grant |
| 03/08/2024 | Date of transaction: Exercise of stock options and sale of shares |
| 03/11/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.